feedback

Course Director

Anthony El-Khoueiry, MD
Anthony El-Khoueiry, MD

USC Norris Comprehensive Cancer Center
Los Angeles, California

Faculty

Jordi Bruix
Jordi Bruix, MD

University of Barcelona
Barcelona, Spain

Richard S. Finn
Richard S. Finn, MD

Geffen School of Medicine at UCLA
Los Angeles, California

Andrew X. Zhu
Andrew X. Zhu, MD, PhD, FACP

Harvard Medical School
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CME
Credit Amount:2.0 Credits
Release Date:2017-Jul-06
Expiration Date:2018-Jul-05
Estimated Time for Completion:120 minutes
Registration Required:No
Cost:Free of Charge

Activity Description and Educational Objectives

The need for additional systemic treatments for patients with advanced hepatocellular carcinoma (HCC) throughout the spectrum of disease has accelerated research into targeted therapies, combination therapy, and immunotherapy as possible additions to the HCC armamentarium. Multi-targeted kinase inhibitors are poised to alter the treatment landscape in both the front-line and second-line settings, while immunotherapy has demonstrated promising early phase results. Personalizing treatment choices for your patients with HCC, while understanding how newer treatment options may fit into the current paradigm poses challenging questions. A panel of experts offers insights into the latest clinical trial results and how new management options may fit into the rapidly changing treatment landscape of HCC.

Upon completion of this activity, participants should be better able to:

  • Assess the benefits and limitations, and clinical role of current and emerging treatment options for advanced HCC
  • Implement evidence-based, individualized treatment regimens for patients with HCC, including new therapies as they are validated for different disease settings and appropriate enrollment in clinical trials
  • Employ effective strategies to monitor and manage the unique adverse effects associated with modern therapies for HCC

Target Audience

This activity has been designed to meet the educational needs of oncologists and other clinicians involved in the management of patients with HCC.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: July 06, 2017 - July 05, 2018
Time to Complete: 120 minutes

Faculty & Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME activity during the past 12 months.

Course Director and Moderator

Anthony El-Khoueiry, MD
Associate Professor of Clinical Medicine
Medical Director of Clinical Investigations Support Office
Phase I program director
USC Norris Comprehensive Cancer Center
Los Angeles, California

Anthony El-Khoueiry, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for AstraZeneca; Bayer HealthCare Pharmaceuticals Inc; Bristol-Myers Squibb; Celgene Corporation; CytomX Therapeutics; Genentech, Inc.; MedImmune; and Transgene.
Grant/Research Support from National Cancer Institute/National Institutes of Health; SWOG; and The Cancer Therapy Evaluation Program (CTEP).
Speakers Bureau participant with Merrimack Pharmaceuticals, Inc.
Advisory Board for AstraZeneca; Bayer HealthCare Pharmaceuticals Inc; Bristol-Myers Squibb; Celgene Corporation; CytomX Therapeutics; Genentech, Inc.; MedImmune; and Transgene.

Anthony El-Khoueiry, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: multi-kinase inhibitors including regorafenib, cabozantinib, lenvatinib, tivantinib; additional targeted agents, immune checkpoint inhibitors targeting PD-1/PDL1 or CTLA4 as well as other immune-based strategies potentially useful for the treatment of hepatocellular carcinoma.

Faculty

Jordi Bruix, MD
Professor of Medicine
University of Barcelona
Director of the Barcelona Clinic Liver Cancer Group
Liver Unit, Hospital Clínic, IDIBAPS. Barcelona, CIBEREHD. Spain
Barcelona, Spain

Jordi Bruix, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Abbott; ArQule; Bayer; Biocompatibles International; Bristol-Myers Squibb; Daiichi Sankyo; F. Hoffmann-La Roche; GlaxoSmithKline; Kowa Pharmaceutical Co. Ltd.; Lilly; and Novartis Pharmaceuticals Corporation.
Grant/Research Support from ArQule; Bayer; and Daiichi Sankyo.
Speakers Bureau participant with Bayer; Biocompatibles International; and Sirtex.
Advisory Board for Bayer; Biocompatibles International; and Novartis Pharmaceuticals Corporation.

Jordi Bruix, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: multi-kinase inhibitors including regorafenib, cabozantinib, lenvatinib, tivantinib; additional targeted agents, immune checkpoint inhibitors targeting PD-1/PDL1 or CTLA4 as well as other immune-based strategies potentially useful for the treatment of hepatocellular carcinoma.

Richard S. Finn, MD
Associate Professor of Medicine
Division of Hematology/Oncology
Geffen School of Medicine at UCLA
Los Angeles, California

Richard S. Finn, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Bayer; Bristol-Myers Squibb; Eisai Inc.; Novartis Pharmaceuticals Corporation; and Pfizer.

Richard S. Finn, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: multi-kinase inhibitors including regorafenib, cabozantinib, lenvatinib, tivantinib; additional targeted agents, immune checkpoint inhibitors targeting PD-1/PDL1 or CTLA4 as well as other immune-based strategies potentially useful for the treatment of hepatocellular carcinoma.

Andrew X. Zhu, MD, PhD, FACP
Professor of Medicine
Harvard Medical School
Director, Liver Cancer Research
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Andrew X. Zhu, MD, PhD, FACP, has a financial interest/relationship or affiliation in the form of:
Consultant for Bayer; Bristol-Myers Squibb; Eisai Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Sanofi.

Andrew X. Zhu, MD, PhD, FACP, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: multi-kinase inhibitors including regorafenib, cabozantinib, lenvatinib, tivantinib; additional targeted agents, immune checkpoint inhibitors targeting PD-1/PDL1 or CTLA4 as well as other immune-based strategies potentially useful for the treatment of hepatocellular carcinoma.

CME Reviewer

Vishwanath Sathyanarayanan, MD, DM
Apollo Hospitals
Bangalore, Karnataka, India

Vishwanath Sathyanarayanan, MD, DM, has no financial interests/relationships or affiliations in relation to this activity.

Medical Director

Marie Becker, PhD
PVI, PeerView Institute for Medical Education

Marie Becker, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit & Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Providership

This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This educational activity is supported through medical education grants from Bayer HealthCare Pharmaceuticals Inc., Bristol-Myers Squibb, Daiichi Sankyo, Inc., Eisai Inc., and Exelixis, Inc.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView Press or any of its partners, providers, and/or supporters.

Copyright © 2000-2017, PeerView Press

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.